Analyst Price Targets — CTMX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 18, 2026 2:16 pm | Roger Song | Jefferies | $16.00 | $4.61 | StreetInsider | CytomX Therapeutics (CTMX) PT Raised to $16 at Jefferies: 'buying opportunity here' |
| March 16, 2026 1:30 pm | Matthew Biegler | Oppenheimer | $12.00 | $8.03 | StreetInsider | CytomX Therapeutics (CTMX) PT Raised to $12 at Oppenheimer |
| February 4, 2026 10:46 am | — | Barclays | $10.00 | $6.07 | TheFly | CytomX Therapeutics price target raised to $10 from $8 at Barclays |
| January 20, 2026 11:48 am | — | Piper Sandler | $10.00 | $5.39 | TheFly | CytomX Therapeutics price target raised to $10 from $6.50 at Piper Sandler |
| January 20, 2026 11:48 am | Michael Schmidt | Guggenheim | $10.00 | $5.39 | TheFly | CytomX Therapeutics initiated with a Buy at Guggenheim |
| January 20, 2026 11:37 am | Etzer Darout | Barclays | $8.00 | $5.39 | TheFly | CytomX Therapeutics price target raised to $8 from $6 at Barclays |
| October 21, 2025 9:19 am | Etzer Darout | Barclays | $6.00 | $3.74 | TheFly | CytomX Therapeutics price target raised to $6 from $3.50 at Barclays |
| September 16, 2025 8:46 pm | Etzer Darout | Barclays | $3.50 | $1.96 | TheFly | CytomX Therapeutics assumed with an Overweight at Barclays |
| July 31, 2025 10:03 am | Matthew Biegler | Oppenheimer | $7.00 | $2.32 | TheFly | CytomX Therapeutics initiated with an Outperform at Oppenheimer |
| November 8, 2024 2:13 pm | Etzer Darout | BMO Capital | $3.68 | $1.09 | StreetInsider | CytomX Therapeutics (CTMX) PT Raised to $3.68 at BMO Capital |
Latest News for CTMX
CytomX Therapeutics, Inc. (NASDAQ: CTMX - Get Free Report) was the target of some unusual options trading activity on Thursday. Stock traders bought 13,090 put options on the stock. This is an increase of approximately 262% compared to the average daily volume of 3,621 put options. Insider Activity at CytomX Therapeutics In other CytomX Therapeutics news,
Adagene (NASDAQ: ADAG - Get Free Report) and CytomX Therapeutics (NASDAQ: CTMX - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, risk, institutional ownership, profitability and valuation. Analyst Recommendations This is a breakdown of current
Assenagon Asset Management S.A. decreased its holdings in shares of CytomX Therapeutics, Inc. (NASDAQ: CTMX) by 18.8% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 592,696 shares of the biotechnology company's stock after selling 137,271 shares during the quarter. Assenagon Asset Management
CytomX Therapeutics, Inc. (NASDAQ: CTMX - Get Free Report) gapped up prior to trading on Thursday after Barclays raised their price target on the stock from $10.00 to $16.00. The stock had previously closed at $4.40, but opened at $4.51. Barclays currently has an overweight rating on the stock. CytomX Therapeutics shares last traded at $4.8370,
On Tuesday, CytomX Therapeutics announced a public offering of 45.9 million shares at $5.30 per share, pre-funded warrants to purchase 1.179 million shares.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CTMX.
U.S. House Trading
No House trades found for CTMX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.